The median duration of treatment was 6.4 months (range 0.03 to 22.0) for patients who received axitinib and 5.0 months (range 0.03 to 20.1) for patients who received sorafenib. Dose modifications or temporary delay of treatment due to an adverse event occurred in 199/359 patients (55%) receiving axitinib and 220/355 patients (62%) receiving sorafenib. Permanent discontinuation due to an adverse event occurred in 33/359 patients (9%) receiving axitinib and 46/355 patients (13%) receiving sorafenib.
The most common (≥20%) adverse reactions observed following treatment with axitinib were diarrhea, hypertension, fatigue, decreased appetite, nausea, weight decreased, dysphonia, palmar-plantar erythrodysesthesia (hand-foot) syndrome, haemorrhage, hypothyroidism, vomiting, proteinuria, cough, and constipation.
The following risks, including appropriate action to be taken, are discussed in greater detail in Precautions: cardiac failure events, hypertension, thyroid dysfunction, arterial thromboembolic events, venous thromboembolic events, elevation of hemoglobin or hematocrit, haemorrhage, gastrointestinal perforation and fistula formation, wound healing complications, RPLS, proteinuria, and elevation of liver enzymes.
Table 2 presents adverse reactions reported in patients who received axitinib.
The adverse reactions are listed by system organ class, frequency category and grade of severity. Frequency categories are defined as: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data). (See Table 2a and Table 2b.)
Click on icon to see table/diagram/image
Click on icon to see table/diagram/image
View ADR Monitoring Form